Novel surgical approach provides 43-month pain relief in a patient with treatment-resistant MS-related trigeminal neuralgia

A case report in Chinese Neurosurgical Journal describes a novel salvage surgical approach for refractory multiple sclerosis-related trigeminal neuralgia. In a single patient who had failed medical, percutaneous, and radiosurgical treatments, the procedure combined internal neurolysis (nerve combing) with targeted glycerol delivery to the proximal trigeminal root. The patient experienced immediate pain relief and remained recurrence-free on the treated side for 43 months, with preserved sensation and reduced medication use.

Multiple sclerosis related trigeminal neuralgia (MS-TN) is one of the most painful neurological complications experienced by people living with multiple sclerosis. Compared with classical trigeminal neuralgia, MS-TN is often more difficult to treat, more likely to recur, and less responsive to both medical and surgical interventions. The condition is believed to arise from demyelination affecting the trigeminal pathways within the brainstem, leading to abnormal nerve signaling and severe episodes of facial pain. For patients who fail conventional therapies, treatment options become increasingly limited.

Now, a case report by Dr. Thomas Patrick Short and Dr. Chandrasekaran Kaliaperumal from the Department of Neurosurgery, Royal Infirmary of Edinburgh, UK, published in Volume 12, Issue 14 of the Chinese Neurosurgical Journal in May 14, 2026, describes a novel salvage surgical approach that provided durable pain relief for a patient with severe, treatment-resistant MS-TN. “Our study reports a salvage surgical approach combining internal neurolysis and targeted proximal trigeminal root glycerol injection for refractory MS-related trigeminal neuralgia,” explains Dr. Short.

The patient was a 50-year-old woman with relapsing-remitting multiple sclerosis who suffered from debilitating right-sided facial pain affecting the maxillary and mandibular branches of the trigeminal nerve. Her symptoms significantly interfered with daily activities such as speaking, eating, and facial contact. Despite extensive treatment, including anticonvulsant medications, two percutaneous glycerol rhizotomies, and Gamma Knife radiosurgery, she continued to experience severe breakthrough pain requiring ongoing medical management. Advanced magnetic resonance imaging demonstrated multiple demyelinating lesions consistent with multiple sclerosis, including abnormalities extending toward the trigeminal root entry zone. Importantly, no evidence of neurovascular compression was identified. Because conventional microvascular decompression relies on the presence of a compressive blood vessel and was therefore not appropriate, the patient was evaluated by a multidisciplinary team to explore alternative treatment strategies. The surgical team performed a retrosigmoid posterior fossa exploration.

During surgery, no neurovascular conflict involving the trigeminal nerve was identified. Internal neurolysis, commonly referred to as “nerve combing,” was performed to mechanically separate trigeminal nerve fascicles without intentionally cutting the nerve fibers, thereby disrupting abnormal signaling pathways that may contribute to pain generation. This was followed by targeted delivery of a small volume of anhydrous glycerol to the proximal cisternal segment of the trigeminal root adjacent to the radiologically relevant demyelinating lesion. The goal was to provide focal chemical neurolysis at a more proximal anatomical location than that targeted during previous percutaneous procedures. The patient experienced immediate postoperative improvement in facial pain. Importantly, sensation in the trigeminal nerve distribution was preserved, and there were no new neurological deficits, corneal dysfunction, or clinically significant facial numbness. Although her early postoperative recovery was complicated by a wound infection requiring surgical washout and antibiotic treatment, no trigeminal nerve–related complications were observed.

Long-term follow-up demonstrated a durable response. Five months after surgery, the patient reported substantial improvement with only occasional residual pain. At one year, she remained free of recurrent trigeminal neuralgia on the treated side, with pain improving from a preoperative Barrow Neurological Institute (BNI) pain intensity score of V to a postoperative score of I, and had significantly reduced her medication requirements. Follow-up evaluations at 19, 26, and 43 months continued to show sustained pain freedom on the operated side. While she later developed intermittent facial pain on the opposite side, this was successfully controlled with low-dose medication and did not represent recurrence of the original symptoms. According to the authors, the case highlights the potential role of root-level surgical strategies in carefully selected patients with refractory MS-TN who have exhausted medical, percutaneous, and radiosurgical options. However, they caution that the findings should be interpreted carefully. “To our knowledge, this represents the first published report of this combined technique in trigeminal neuralgia secondary to multiple sclerosis,” said Dr. Short.

The authors conclude that this novel approach should be regarded as hypothesis-generating rather than practice-defining. Nevertheless, the durable pain relief observed in this highly challenging case suggests that further research may be warranted to evaluate whether combined internal neurolysis and targeted proximal trigeminal root glycerol delivery could offer a future salvage option for selected patients with treatment-resistant multiple sclerosis–related trigeminal neuralgia.